CHINA CARDIOVASCULAR ULTRASOUND MARKET FORECAST 2026-2034

China’s government has responded with decisive policy action. The Healthy China 2030 initiative explicitly targets cardiovascular disease prevention as a national priority, anchoring the expansion of cardiac diagnostic infrastructure, including cardiovascular ultrasound, within the country’s primary healthcare strengthening roadmap. Government procurement of medical imaging equipment has scaled meaningfully in recent years, with public hospitals remaining the dominant buyers through centralized tendering frameworks that influence pricing and vendor selection across the market.

At the same time, the push to extend diagnostic services into lower-tier cities and rural regions is opening new access points for portable and point-of-care cardiac ultrasound systems, broadening the market well beyond the Tier 1 city hospital clusters that have historically driven volume. These intersecting forces, a massive and growing patient pool, active government investment, and expanding geographic reach, give the China cardiovascular ultrasound market a growth profile that is both deep and durable over the forecast period.

The China cardiovascular ultrasound market is segmented by device display, technology, application, type, and end-user. The application segment is further categorized into diagnostic applications and therapeutic applications.

Diagnostic applications represent the dominant sub-segment within the application segment of the China cardiovascular ultrasound market. Their commanding position reflects the fundamental clinical role that cardiac imaging plays across the continuum of cardiovascular care in China. In a market where cardiovascular disease is the leading cause of death, and where the incidence of acute myocardial infarction, coronary heart disease, and stroke continues to rise, as confirmed by the National Health Commission’s health statistics, the demand for reliable, non-invasive cardiac diagnostics is structurally embedded into everyday clinical practice across China’s vast hospital network.

Diagnostic applications encompass a broad range of cardiac assessments, including structural evaluation through the transthoracic echocardiogram, detailed anatomical imaging via transesophageal echocardiogram, and functional cardiac stress testing. Together, these procedures form the diagnostic backbone of cardiology departments in China’s public hospitals, which account for the majority of cardiac ultrasound procurement nationwide. Adding to this, the Healthy China 2030 initiative’s focus on preventive care and early detection is further accelerating diagnostic application volumes, as primary care facilities increasingly integrate cardiovascular screening protocols into routine health management.

The growing adoption of AI-assisted diagnostic tools within cardiovascular ultrasound platforms is also enhancing throughput and consistency in clinical workflows, particularly in hospitals that face high patient volumes and constrained specialist capacity. As a result, for vendors operating in the cardiovascular imaging market, the diagnostic applications sub-segment offers both scale and longevity. It is the segment where replacement cycles are most predictable, clinical workflows are most established, and government reimbursement frameworks are best aligned with equipment investment.

Some of the top players operating in the China cardiovascular ultrasound market include CHISON Medical Technologies Co Ltd, Mindray Medical International Limited, GE HealthCare, Koninklijke Philips NV, Siemens Healthineers AG, etc.

CHISON Medical Technologies Co Ltd is a Wuxi, Jiangsu-headquartered ultrasound manufacturer and one of China’s most established domestic players in the cardiovascular ultrasound market. CHISON has built a portfolio that spans cart-based systems, portable units, and handheld devices, with dedicated cardiovascular imaging solutions designed for cardiologists across a range of clinical settings, from large public hospitals to community health centers.

The company’s cardiovascular ultrasound lineup, including the XBit 90 with advanced TEE imaging capabilities and the SonoMax system powered by its MAX++ platform, addresses the full spectrum of cardiac diagnostic procedures, from routine transthoracic echocardiogram workflows to complex structural heart assessments.

Moreover, CHISON is certified by regulatory authorities across key markets, including CE (EU), FDA (US), KFDA (South Korea), and CSA (Canada), supporting its presence in over 100 countries, while its domestic manufacturing base and competitive pricing give it a natural advantage within China’s centralized hospital procurement environment, where cost-efficiency and local support infrastructure are decisive buying criteria.